Their baseline clinicopathologic data, including age, gender, pretreatment clinical T and N stage, pretreatment carcinoembryonic antigen (CEA), tumor location, and size, were derived from medical records (Table 1). This evidence concerns the gene CEACAM5 and neoplasm.